Open Payments

St. Lukes Hospital

Type
Teaching hospital
Where
SAN FRANCISCO, CA
Medicare CCN
050055
Received
$1,205,141 in 120 records, 2020 ($960 general, $1,204,181 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment5$960
2020Research payment115$1,204,181

By company

CompanyRecordsAmountYears
E.R. Squibb & Sons, L.L.C.17$445,9012020
Edwards Lifesciences Corporation37$357,2152020
Biogen, Inc.5$215,2532020
Novartis Pharmaceuticals Corporation6$85,4452020
CSL Behring20$54,0522020
Alexion Pharmaceuticals, Inc.6$13,5732020
BIOTRONIK INC.5$11,8002020
SK Life Science, Inc.13$10,5082020
Incyte Corporation4$8,5002020
Celgene Corporation1$1,5002020
Zimmer Biomet Holdings, Inc.2$6502020
NEUROPACE, INC.1$4302020
Stryker Corporation2$1972020
GenMark Diagnostics, Inc.1$1122020

By nature of payment

NatureRecordsAmount
Research payment115$1,204,181
Gift4$847
Food and Beverage1$112

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-23Edwards Lifesciences Corporation$13,080Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-12-23Incyte Corporation$4,500Research paymentCash or cash equivalentA Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-23Incyte Corporation$1,500Research paymentCash or cash equivalentA Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-23Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-17Edwards Lifesciences Corporation$24,759Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072020
2020-12-16Celgene Corporation$1,500Research paymentCash or cash equivalentRevlimid Drug, HematologyCelgene - Connect MDS/AML2020
2020-12-10Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesTHE ENCIRCLE Trial (#2018-19)2020
2020-12-03Alexion Pharmaceuticals, Inc.$7,000Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and 2020
2020-12-03Alexion Pharmaceuticals, Inc.$3,500Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and 2020
2020-12-03Edwards Lifesciences Corporation$2,200Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesSM3 Trial 2017-032020
2020-12-03Alexion Pharmaceuticals, Inc.$1,200Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and 2020
2020-12-03Alexion Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and 2020
2020-12-03Alexion Pharmaceuticals, Inc.$550Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and 2020
2020-11-23Edwards Lifesciences Corporation$34,156Research paymentCash or cash equivalentSM3 Trial 2017-032020
2020-11-12Novartis Pharmaceuticals Corporation$750Research paymentCash or cash equivalentTAFINLAR Drug, ONCOLOGYCOMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER2020
2020-11-11CSL Behring$2,965Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$1,428Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$1,342Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$1,045Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$963Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$632Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$408Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$365Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$261Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$62Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-11CSL Behring$18Research paymentIn-kind items and servicesHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-11-10SK Life Science, Inc.$1,653Research paymentCash or cash equivalentCenobamate Drug, Neurology0595662020
2020-11-10CSL Behring$1,500Research paymentCash or cash equivalentHaegarda Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-11-10CSL Behring$265Research paymentCash or cash equivalentHaegarda Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-11-05Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesSM3 Trial 2017-032020
2020-11-05E.R. Squibb & Sons, L.L.C.$121Research paymentCash or cash equivalentOPDIVO Biological, OncologyPh III NSCLC 2L, non-squamous2020
2020-11-02Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-11-02Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-10-28Novartis Pharmaceuticals Corporation$424Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYAN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM2020
2020-10-26Edwards Lifesciences Corporation$7,037Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-10-26Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesTHE ENCIRCLE Trial (#2018-19)2020
2020-10-22Edwards Lifesciences Corporation$11,427Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072020
2020-10-20Novartis Pharmaceuticals Corporation$484Research paymentCash or cash equivalentPDR001 BiologicalA RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETIN2020
2020-10-19Edwards Lifesciences Corporation$1,500Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesPARTNER3 2015-082020
2020-10-19Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesTHE ENCIRCLE Trial (#2018-19)2020
2020-10-08Edwards Lifesciences Corporation$1,000Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesEarly-TAVR Trial #2016-072020
2020-10-08Edwards Lifesciences Corporation$500Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesPartner3 2015-082020
2020-10-05Edwards Lifesciences Corporation$17,000Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesTHE ENCIRCLE Trial (#2018-19)2020
2020-10-01Edwards Lifesciences Corporation$22,566Research paymentCash or cash equivalentPartner3 2015-082020
2020-10-01Edwards Lifesciences Corporation$19,053Research paymentCash or cash equivalentSM3 Trial 2017-032020
2020-10-01CSL Behring$7,800Research paymentCash or cash equivalentHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-10-01CSL Behring$3,250Research paymentCash or cash equivalentHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-10-01CSL Behring$2,000Research paymentCash or cash equivalentHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-10-01Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesEarly-TAVR Trial #2016-072020
2020-10-01CSL Behring$725Research paymentCash or cash equivalentHizentra Biological, ImmunologyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu2020
2020-09-28NEUROPACE, INC.$430Research paymentCash or cash equivalentRNS System Device, EpilepsyRNS Long Term Trmt Clin Trial2020
2020-09-18SK Life Science, Inc.$1,458Research paymentCash or cash equivalentCenobamate Drug, Neurology595662020
2020-09-10Edwards Lifesciences Corporation$2,200Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesSM3 Trial 2017-032020
2020-09-10Alexion Pharmaceuticals, Inc.$573Research paymentCash or cash equivalentSafety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis2020
2020-09-04E.R. Squibb & Sons, L.L.C.$250Research paymentCash or cash equivalentYERVOY Biological, OncologyPhIII Adjuvant Melanoma EORTC2020
2020-08-27Edwards Lifesciences Corporation$57,503Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072020
2020-08-21E.R. Squibb & Sons, L.L.C.$44,470Research paymentCash or cash equivalentOPDIVO Biological, OncologyPh IIb 2L Bladder Registrational2020
2020-08-18BIOTRONIK INC.$1,500Research paymentCash or cash equivalentBioMonitor 2 Device, Cardiology/Vascular DiseasesBIOGUARD-MI2020
2020-08-18BIOTRONIK INC.$500Research paymentCash or cash equivalentBioMonitor 2 Device, Cardiology/Vascular DiseasesBIOGUARD-MI2020
2020-08-12SK Life Science, Inc.$886Research paymentCash or cash equivalentCenobamate Drug, Neurology595662020
2020-07-30CSL Behring$1,653Research paymentCash or cash equivalentHaegarda Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-07-29Novartis Pharmaceuticals Corporation$22,438Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF)2020
2020-07-24SK Life Science, Inc.$783Research paymentCash or cash equivalentCenobamate Drug, Neurology595662020
2020-07-14SK Life Science, Inc.$572Research paymentCash or cash equivalentCenobamate Drug, Neurology595662020
2020-07-09Edwards Lifesciences Corporation$47,560Research paymentCash or cash equivalentSM3 Trial 2017-032020
2020-07-08E.R. Squibb & Sons, L.L.C.$164,058Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Melanoma 2 3L IPI Progressors2020
2020-07-02Edwards Lifesciences Corporation$22,035Research paymentCash or cash equivalentPARTNER3 2015-082020
2020-06-18Edwards Lifesciences Corporation$2,175Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-06-16BIOTRONIK INC.$50Research paymentCash or cash equivalentBioMonitor 2 Device, Cardiology/Vascular DiseasesBIOGUARD-MI2020
2020-06-11Edwards Lifesciences Corporation$500Research paymentCash or cash equivalentTrial #2017-18 ExCEED2020
2020-06-08E.R. Squibb & Sons, L.L.C.$5,363Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma2020
2020-06-01Biogen, Inc.$458Research paymentIn-kind items and servicesMethodology Study of Novel Outcome Measures to Assess Progression of ALS2020
2020-06-01SK Life Science, Inc.$455Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-05-27SK Life Science, Inc.$1,027Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-05-19E.R. Squibb & Sons, L.L.C.$42,076Research paymentCash or cash equivalentOPDIVO Biological, OncologyPh III registrational study in 1L HCC nivo monotherapy2020
2020-05-15SK Life Science, Inc.$810Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-05-13E.R. Squibb & Sons, L.L.C.$16,838Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III NSCLC 1L combo2020
2020-05-08E.R. Squibb & Sons, L.L.C.$6,054Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase II 1L Mel - IPI Combo2020
2020-05-07SK Life Science, Inc.$14Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-04-30Stryker Corporation$114GiftIn-kind items and servicesULTRA COMFORT SURFACE Device, PATIENT HANDLING - PH2020
2020-04-30Stryker Corporation$82GiftIn-kind items and servicesULTRA COMFORT SURFACE Device, PATIENT HANDLING - PH2020
2020-04-28Edwards Lifesciences Corporation$2,825Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesPARTNER3 2015-082020
2020-04-24GenMark Diagnostics, Inc.$112Food and BeverageIn-kind items and servicesePlex Device, Devices2020
2020-04-23Edwards Lifesciences Corporation$1,390Research paymentCash or cash equivalentEarly Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C2020
2020-04-20Zimmer Biomet Holdings, Inc.$0GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2020
2020-04-16CSL Behring$769Research paymentCash or cash equivalentHaegarda Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-04-15Zimmer Biomet Holdings, Inc.$650GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2020
2020-04-14Incyte Corporation$1,500Research paymentCash or cash equivalentA Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome2020
2020-04-09Edwards Lifesciences Corporation$34,917Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072020
2020-04-08E.R. Squibb & Sons, L.L.C.$6,355Research paymentCash or cash equivalentEvaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (Belatac2020
2020-04-01SK Life Science, Inc.$1,830Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-04-01Novartis Pharmaceuticals Corporation$1,778Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYRIBOCICLIB + STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR+HER2-EARLY BC AT HIGH RISK FOR RECURRENCE2020
2020-04-01SK Life Science, Inc.$143Research paymentCash or cash equivalentCenobamate Drug, Neurology1-FA77592020
2020-03-24BIOTRONIK INC.$250Research paymentCash or cash equivalentBioMonitor 2 Device, Cardiology/Vascular DiseasesBIOGUARD-MI2020
2020-03-18Edwards Lifesciences Corporation$1,500Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesPARTNER3 2015-082020
2020-03-17BIOTRONIK INC.$9,500Research paymentCash or cash equivalentBioMonitor 2 Device, Cardiology/Vascular DiseasesBIOGUARD-MI2020
2020-03-09E.R. Squibb & Sons, L.L.C.$28,758Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Monotherapy2020
2020-03-09Edwards Lifesciences Corporation$7,212Research paymentCash or cash equivalentPartner3 2015-082020
2020-03-06Edwards Lifesciences Corporation$1,337Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-03-04Edwards Lifesciences Corporation$8,615Research paymentCash or cash equivalentEarly Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C2020
2020-03-03SK Life Science, Inc.$91Research paymentCash or cash equivalentCenobamate Drug, NeurologyAn Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O2020
2020-03-02Biogen, Inc.$2,700Research paymentCash or cash equivalentTYSABRI Biological, NEUROLOGYPhase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy2020
2020-02-25Edwards Lifesciences Corporation$1,000Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesEarly-TAVR Trial #2016-072020
2020-02-20E.R. Squibb & Sons, L.L.C.$11,402Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant HCC mono vs placebo2020
2020-02-18CSL Behring$26,595Research paymentIn-kind items and servicesBerinert Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-02-12Edwards Lifesciences Corporation$837Research paymentCash or cash equivalentCLASP IID 2018-072020
2020-02-05E.R. Squibb & Sons, L.L.C.$27,097Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Stage II B C Opdivo Mono2020
2020-02-05Edwards Lifesciences Corporation$650Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesSM3 Trial 2017-032020
2020-02-04Biogen, Inc.$87,835Research paymentCash or cash equivalentLong-Term Evaluation of BIIB0672020
2020-02-03SK Life Science, Inc.$783Research paymentCash or cash equivalentCenobamate Drug, NeurologyAn Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O2020
2020-01-31Edwards Lifesciences Corporation$2,200Research paymentCash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart ValvesSM3 Trial 2017-032020
2020-01-29Edwards Lifesciences Corporation$2,200Research paymentCash or cash equivalentEarly Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C2020
2020-01-27E.R. Squibb & Sons, L.L.C.$36,847Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF22020
2020-01-27E.R. Squibb & Sons, L.L.C.$30,847Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF22020
2020-01-22Novartis Pharmaceuticals Corporation$59,571Research paymentCash or cash equivalentPDR001 DrugMODULAR PHASE 2 STUDY TO LINK COMBINATION IMMUNE THERAPY TO PATIENTS WITH ADVANCED SOLID AND HEMATOLOGIC MALIGNANCIES MO2020
2020-01-21E.R. Squibb & Sons, L.L.C.$21,431Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Nivo Ipi vs Placebo in Adjuvant RCC2020
2020-01-21Biogen, Inc.$7,348Research paymentCash or cash equivalentPLEGRIDY Biological, NEUROLOGYPlegridy Observational Program2020
2020-01-21E.R. Squibb & Sons, L.L.C.$1,856Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Bladder nivo mono2020
2020-01-06E.R. Squibb & Sons, L.L.C.$2,071Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Study Adj GEJ & Esoph US EU mono2020
2020-01-01Biogen, Inc.$116,912Research paymentCash or cash equivalentAn Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyot2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.